A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP

Digestive Diseases and Sciences

Volumn 51, Issue 4, 2006, Pages 808-812

  Murashima, Shiro ^a   Tanaka, Masatoshi ^a   Haramaki, Makoto ^a   Yutani, Shigeru ^a   Nakashima, Yutaka ^a   Harada, Kazunori ^a   Ide, Tatsuya ^a   Kumashiro, Ryukichi ^a   Sata, Michio ^a  

^a KURUME UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

fetoprotein; Hepatitis C; Hepatocellular carcinoma; Interferons

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; GLYCYRRHIZIC ACID; NEOMINOPHAGEN C; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG EFFECT; DRUG SYNTHESIS; FEMALE; HEPATITIS C; HIGH RISK POPULATION; HUMAN; INFECTION PREVENTION; INFECTION RISK; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER PROTECTION; LONG TERM CARE; LOW DRUG DOSE; MALE; PREDICTION; PRIORITY JOURNAL; THROMBOCYTE COUNT;

AGED; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 33645848470     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-3211-2     Document Type: Article

References (19)

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965, 2001
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982, 2002
3. Takano S, Ito Y, Yokosuka O, Ohio M, Uchiumi K, Hirota K, Omata M: A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 22:1002, 1995
4. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, Suzuki Y, Saitoh S, Kobayashi M, Kumada H: The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 79:1949-1500, 1997
5. van Rossum TG, Vulto AG, Hop WC, Brouwer JT, Niesters HG, Schalm SW: Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial: J Gastroenterol Hepatol 14:1093-1099, 1999
6. Szymendera JJ, Zborzil J, Sikorowa L, Lenko J, Kaminska JA, Gadek A: Evaluation of five tumor markers (AFP, CEA, hCG, hPL and SP1) in monitoring therapy and follow-up of patients with testicular germ cell tumors. Oncology 40:1-10, 1983
7. Okuda K, Kotoda K, Obata H, Hayashi N, Hisamitsu T: Clinical observations during a relatively early stage of hepatocellular carcinoma, with special reference to serum alpha-fetoprotein levels. Gastroenterology 69:26-234, 1975
8. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, Kumada H: A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 18:47-53, 1993
9. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H: Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 428:1797-1801, 1993
10. Hu KQ, Kyulo NL, Lim N, Elhazin B, Hillebrand DJ: Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol 99:860-865, 2004
11. Alpert E: Serum alpha-fetoprotein (AFP) in benign and malignant gastrointestinal diseases: evaluation of an immunoenzymatic assay. Clin Chim Acta 58:77-83, 1975
12. Jagiello-Wojtowicz E, Rzeszowska G, Krawczuk G, Baran E, Surmaczynska B, Fijalka-Rymar M, Bielec D: Alpha-fetoprotein in acute viral hepatitis type A. Przegl Epidemiol 47:17-20, 1993
13. Francioni S, Pastore M: Alpha-fetoprotein and acute viral hepatitis type B. J Nucl Med Allied Sci 33(Suppl 3):103-106, 1989
14. Pastore G, Lapedota E, Dentico P, Buongiorno R, Mallardi M, Angarano G, Schiraldi: Prognostic value of alpha-foetoprotein in fulminant hepatitis. Quad Sclavo Diagn 15:14-21, 1979
15. Innis MA, Miller DL: alpha-Fetoprotein gene expression. Control of alpha-fetoprotein mRNA levels in cultured rat hepatoma cells. J Biol Chem 254:9148-9154, 1979
16. Yoshida T, Hanada T, Tokuhisa T, Kosai K, Sata M, Kohara M, Yoshimura A: Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med 196:641-653, 2002
17. Yano H, Iemura A, Haramaki M, Ogasawara S, Takayama A, Akiba J, Kojiro M: Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology 29:1708-1717, 1999
18. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, Shiomi S, Tamori A, Oka H, Igawa S, Kuroki T, Kinoshita H: Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 134:963-967, 2001
19. Sakon M, Nagano H, Dono K, Nakamori S, Umeshita K, Yamada A, Kawata S, Imai Y, Iijima S, Monden M: Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 94:435-442, 2002